View Post

Updated recommendations for managing hereditary breast cancer

In Clinical Studies News by Barbara Jacoby

Source: Health Day From: medicalxpress.com One year of adjuvant olaparib should be offered to patients with high-risk early-stage human epidermal growth factor receptor 2 (HER2)-negative breast cancer and germline BRCA mutations after completion of (neo)adjuvant chemotherapy and local treatment, according to a rapid recommendation update published by the American Society for Clinical Oncology (ASCO). Following presentation of the results from …

View Post

Popular breast cancer drugs don’t work the way we thought they did

In Clinical Studies News by Barbara Jacoby

By: Lisa Marshall From: colorado.edu Some of the most commonly used drugs for treating hereditary breast and ovarian cancers may not work the way we thought they did, according to new CU Boulder research. The paper, published Feb. 2 in the journal Nature Communications, sheds new light on how they do work and could open the door to new next-generation medications …

View Post

Many supposed breast cancer risk genes don’t raise risk, studies find

In In The News by Barbara Jacoby

By: Marie McCullough, The Philadelphia Inquirer From: medicalxpress.com In the quarter century since the watershed discovery of BRCA1 and BRCA2, dozens of other genes have been implicated in hereditary breast cancer. A slew of commercial tests are now available that look for mutations in those breast cancer “predisposition genes” to help guide health-care decisions. The thing is, some of the …

View Post

Hereditary Cancer: When Should You Be Screened?

In In The News by Barbara Jacoby

By: Ryan Bisson, MS, CGC Genetic Counselor From: orlandohealth.com Only 5 to 10 percent of all cancers are hereditary, but research reveals that family history can increase your chances of developing cancer. Factors that determine your risk include the type of cancer in your family, how old your relatives were when they were diagnosed, and whether other family members have …